Laurus Labs announced that US Food and Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) at its manufacturing facility at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was conducted from 24 October 2022 to 28 October 2022. The company has been issued a Form 483 with one observation. The observation is procedural in nature. The Company will address the observation within stipulated timelines. Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
